OSE Immunotherapeutics has shared phase 2 data on its neo-epitope vaccine candidate and Keytruda in ovarian cancer, linking ...

Exelixis EXEL announced a clinical development collaboration with pharma giant Merck & Co. MRK to evaluate its pipeline candidate, zanzalintinib, in combination with subcutaneous Keytruda Qlex in the ...

The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...

By Siddhi Mahatole May 21 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment ...

Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body ...

Go behind the scenes of the Cancer Calculus investigation, and hear insights about Merck's cancer drug Keytruda from ICIJ's ...

ASCO is just around the corner, and as usual, there is a fertile crop of high-profile clinical trials to look out for among the late-breaker presentations. To follow – and in no particular order - are ...

Read all the latest news headline updates on cancer drugs. Get all the cancer drugs breaking news updates, videos, photostories and more at Business Standard.

Flatiron Health today announced its presence at the American Society of Clinical Oncology (ASCO) Annual Meeting happening from May 29 - June 2, 2026, in Chicago, Illinois. Flatiron's high-quality real ...

The company’s partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment in lung ...